Submitted by HLeSueur on 13 November 2015
Amplyx Pharmaceuticals announced on Wednesday that they have secured $40.5 million to advance the development of APX001. APX001 is a new antifungal drug with a novel mechanism of action. Resistance, including cross-resistance between antifungals in the same class (e.g. Azoles), is a growing problem which demonstrates the critical need for new classes of effective antifungal agents. The president of Amplyx Pharmaceuticals recognised this, saying ‘there is an urgent unmet need for new treatments for fungal infections which increasingly impact immune-compromised patients who are at high risk of contracting these difficult-to-treat, and often deadly, infections.” Indeed, there hasn’t been a new class of antifungal drug approved since 2001.
Amplyx Pharmaceuticals are taking a step in the right direction. APX001 has shown broad-spectrum activity in animal models of invasive fungal infection by Candida and Aspergillus, as well as in rare, difficult to treat moulds. Phase 1 clinical trials are scheduled for 2016.
News archives
-
Title
Date
